Combo can produce durable remissions in PTCL



horowitz-steven-3-larry-young_230.jpg
Steven Horwitz, MD
Photo by Larry Young

A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-cell lymphoma (PTCL), results of a phase 1 study suggest. The patients received brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisolone (BV+CHP). In some cases, this was followed by BV monotherapy. The estimated 3-year... [Read Article]

Chemo regimen can be ‘highly effective’ against ENKTL



Huang_Huiqiang _LarryYoung_230.jpg
Hui-Qiang Huang, MD, PhD
Photo by Larry Young

A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell lymphoma (ENKTL), according to researchers. In a single-center study, this regimen—pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX)—followed by extensive involved-field radiotherapy (EIFRT) produced high rates of long-term overall survival (OS) and progression-free... [Read Article]

Dual inhibitor could treat ATLL



Yamagishi_Makoto_Credit_LarryYoung-230.jpg
Maokoto Yamagishi, PhD
Photo by Larry Young

Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-cell leukemia/lymphoma (ATLL). The compound, known as OR-S1, has demonstrated activity against ATLL in vitro and in vivo. Researchers said OR-S1 reversed epigenetic disruption in ATLL cells, selectively eliminated both ATLL... [Read Article]

Immunotherapy proves active against MF, SS



Kim_Youn-LarryYoung-230.jpg
Youn Kim, MD
Photo by Larry Young

The PD-1-blocking antibody pembrolizumab can produce “significant objective clinical responses” in patients with relapsed or refractory cutaneous T-cell lymphoma, according to researchers. The drug elicited partial responses in 33% of patients enrolled in a phase 2 study. Half of the responders had mycosis fungoides (MF), and half... [Read Article]

Mutations may impact response to HDACis in PTCL-NOS



Ji-Meng-Meng_LarryYoung_230.jpg
Meng-Meng Ji, MD, PhD
Photo by Larry Young

Preclinical research has revealed mutations that may affect the performance of histone deacetylase inhibitors (HDACis) in patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The researchers identified histone-modifying gene mutations in patients with PTCL-NOS and found evidence to suggest these mutations confer shorter survival. The team... [Read Article]

Lenalidomide shows promise for treating ATLL



Nosaka_Kisato_LarryYoung-230.jpg
Kisato Nosaka, MD, PhD
Photo by Larry Young

Results of a phase 2 trial suggest lenalidomide may be a treatment option for patients with relapsed adult T-cell leukemia-lymphoma (ATLL). Lenalidomide produced a 42% overall response rate (ORR) in this trial, and patients had a “favorable” median overall survival, according to Kisato Nosaka, MD, PhD,... [Read Article]

Study suggests chidamide could treat rel/ref CTCL too



Shi_Yuankai_LarryYoung-230.jpg
Yuankai Shi, MD, PhD
Photo by Larry Young

The oral histone deacetylase inhibitor chidamide can elicit responses in patients with relapsed or refractory cutaneous T-cell Lymphoma (CTCL), a new study suggests. Chidamide has already demonstrated efficacy against relapsed or refractory peripheral T-cell lymphoma and has been approved for this indication in China. Now, results... [Read Article]